ISHARES TRUST ISHARES BIOTECHNOLOGY ETF (IBB) - Price, trends, fundamentals and chart - Passport to Wall Street

ISHARES TRUST ISHARES BIOTECHNOLOGY ETF (NASDAQ: IBB)

Overview

current price

$217.86

$217.86

change

0.00 | 0.00%

0.00 | 0.00%

Yesterday's Close

217.86

open

0.00

volume

0.00 M

30d. avg volume.

1.63 M

1 day

0.00 - 0.00

52 weeks

154.62 - 217.12

p/e

0.00

beta

0.6937

market cap

11.35 B

dividend yield

0.16%

Industry

-

News and Commentary

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc ...

Moderna Advances Ebola Vaccine Into Human Testing Moderna Inc. (MRNA

Rising Stars, Falling Trends: July's Industry ETF Winners and Losers As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month.Among the largest ETFs that represent ma...

FDA Approves Alzheimer's Drug Slowing Cognitive Decline The Food and Drug Administration (FDA) announced accelerated approval for lecanemab which showed evidence that it was able to slow cognitive decline in people with mild impairmen...

Here’s Why Investors Should Consider Biotech, Pharmaceutical Stocks The financial markets are not the most pleasant and calm place right now. It's facing risks in multiple areas such as geopolitics, inflation, and economic growth. There's also th...

Biotech ETFs May Need to Prepare for More Losses Ahead Biotechnology stocks faced their worst April on record, and more pain may be ahead for biotech-focused exchange traded funds (ETF).Popular biotech-focus...

Biotechs Setting up for a Strong 2021 From 2009 to the middle of 2015, biotechs were one of the strongest sectors in the market. Over this period, the iShares Nasdaq Biotechnology ETF

Moderna Vaccine Update May Boost Biotech ETFs Moderna (MRNA

Biotechs Break Out to New Highs For the past couple of years, the biotech sector (

Biotechs Setting Up, Fundamentals Improving The biotech sector is exhibiting remarkable strength and resilience during these turbulent market conditions. Interestingly, biotechs were actually a laggard during the last leg...

StockTwits

StockTwits

Join now and unlock premium features

Access to premium stock and ETF data including financials, holdings and more
Participate in trading contests and earn real prizes
Sync you favorite articles and symbols between all of your device
And much more